The Industry’s Preeminent Event on Novel Drug Targets

ABOUT THIS CONFERENCE 

To date, several widespread and promising second-generation epigenetic drug development campaigns have been dedicated to the modulation of histone methylation. In this post-genomic era of drug development, the identification of genetic mutations and overexpression of histone methyltransferases (HMTs) across a variety of cancer types provide unique validation for selective and tumor-specific targeting of methyltransferase enzymes. Significant progress has been seen in the development of potent, selective and tolerable inhibitors against several HMTs, including the first inhibitor to enter human clinical trials. Yet, with several HMT targets and inhibitors poised for further development, there is great need for advanced tools to perturb methylation environments in normal and disease states. Building on the success of last year, Cambridge Healthtech Institute's Second Annual Targeting Histone Methyltransferases conference is the preeminent event for HMTi development, gathering a diverse cross-section of academic and industry leaders actively working on advancing second-generation epigenetic therapies.

Day 1 | Day 2 | Download Brochure   

Tuesday, September 24

7:00 am Registration and Morning Coffee

FEATURED SESSION: LEADERS IN EPIGENETIC DRUG DISCOVERy

8:10 Chairperson’s Opening Remarks

8:15 Drugging the Epigenome

Cheryl H. Arrowsmith, Ph.D., Chief Scientist, Structural Genomics Consortium; Professor, Medical Biophysics; Canada Research Chair, StructuralProteomics, University of Toronto

9:00 Talk Title to be Announced

Peter J. Tummino, Ph.D., Head, Biology, Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals

9:45 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

STATE OF THE ART IN LYSINE METHYLTRANSFERASE PROBES & INHIBITORS

10:45 A First-in-Class Chemical Probe for SETD7

Dafydd Owen, Ph.D., Associate Research Fellow, Medicinal Chemistry, Pfizer Worldwide R&D

11:15 Sponsored Presentation (Opportunity Available)

11:45 Targeting Histone Methyltransferases in Cancer Therapy

Sarah Knutson, Ph.D., Senior Scientist, Biological Sciences, Epizyme

12:15 pm Therapeutic Applications of EZH2 Small Molecule Inhibitors

Patrick Trojer, Ph.D., Senior Director & Head, Biology, Constellation Pharmaceuticals

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

Mechanistic Insights into oncogenesis and targeted therapy

2:15 Chairperson’s Opening Remarks

2:20 Targeting H3K4 Methylation by the MLL1 Complex for the Treatment of Mixed Lineage Leukemia

Yali Dou, Ph.D., Associate Professor, Pathology, University of Michigan

2:50 Small Molecule Epigenetic Intervention of Disease via Histone Lysine Methyltransferases

Matthew Fuchter, Ph.D., Senior Lecturer, Synthetic and Medicinal Chemistry, Department of Chemistry, Imperial College London

3:20 Sponsored Presentation (Opportunity Available)

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Harnessing EZH2 Enzymatic Activities by Targeting PRC2 Associated Cofactors

Gang “Greg” Wang, Ph.D., Assistant Professor, Department of Biochemistry & Biophysics, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

5:00 Targeting the Histone Methyltransferase MMSET in Cancer

Irfan Asangani, Ph.D., Research Investigator, Pathology, Michigan Center for Translational Pathology, University of Michigan

5:30 Interactive Breakout Discussion Groups

6:30 Welcome Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

Day 1 | Day 2 | Download Brochure